DSK Legal Advises HealthQuad Fund II In Its Investment In Beta Drugs Limited
DSK Legal represented and advised HealthQuad Fund II in its investment in Beta Drugs Limited, a listed entity, through the subscription of equity shares and compulsory convertible debentures. Other investors participating in this funding round included Inti Capital VCC – Inti Capital I and Generational Capital Breakout Fund 1.
Beta Drugs is engaged in the manufacturing, distribution, and sale of pharmaceutical products across domestic and international markets, specialising in oncology-focused formulations.
DSK Legal’s Team comprised Partner Nakul Batra, Principal Associate Palak Sehgal, Senior Associate Singh, Associates Aankhi Anwesha and Daksh Krishnan.
Source: DSK Legal’s LinkedIn Page
